Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Wellnex Life Ltd ( (AU:WNX) ) just unveiled an update.
Wellnex Life Limited reported a 40.5% increase in revenue for FY25, reaching A$23.6 million, driven by the full-year contribution from its Pain Away brand. Despite a net loss of A$15.6 million, the company improved its gross margin in the second half of the year through a refined trade investment strategy. The dual listing on the AIM Market and associated capital raising helped settle significant financial obligations, positioning Wellnex for future growth. The company aims to enhance revenue and margins in FY26 by leveraging its leading Pain Away brand and expanding contract manufacturing partnerships.
More about Wellnex Life Ltd
Wellnex Life Limited operates in the health and pharmaceutical industry, focusing on the development, marketing, and selling of premium brands and products. The company also licenses its innovative products to domestic and global pharmaceutical companies.
For a thorough assessment of WNX stock, go to TipRanks’ Stock Analysis page.